INMED PHARMACEUTICALS INC. Payment for Contingent Consideration Liability, Investing Activities
INMED PHARMACEUTICALS INC. (INM) reported Payment for Contingent Consideration Liability, Investing Activities of $500.00 thousand for the 12-month period ending 2023-06-30, per its 10-K filed 2023-09-29.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities · last filed 2024-02-13
- INMED PHARMACEUTICALS INC. payment for contingent consideration liability, investing activities for the quarter ending 2023-06-30 was $0.00.
- INMED PHARMACEUTICALS INC. payment for contingent consideration liability, investing activities for the quarter ending 2023-03-31 was $0.00.
- INMED PHARMACEUTICALS INC. payment for contingent consideration liability, investing activities for fiscal 2023 was $500.00K, a 66.41% increase from fiscal 2022.
- INMED PHARMACEUTICALS INC. payment for contingent consideration liability, investing activities for fiscal 2022 was $300.46K.
| Period end | Payment for Contingent Consideration Liability, Investing Activities 3 month | Payment for Contingent Consideration Liability, Investing Activities 6 month | Payment for Contingent Consideration Liability, Investing Activities 9 month | Payment for Contingent Consideration Liability, Investing Activities 12 month |
|---|---|---|---|---|
| 2023-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-29 | $0.00 derived: sum of 2 quarters · filed 2023-09-29 | $500.00K 10-K · filed 2023-09-29 | |
| 2023-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-15 | $500.00K 10-Q · filed 2023-05-15 | ||
| 2022-12-31 | $500.00K 10-Q · filed 2024-02-13 | |||
| 2022-06-30 | $300.46K 10-K · filed 2023-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |